Company:  TRIUS THERAPEUTICS INC
Form Type:  8-K
Filing Date:  4/3/2013 
CIK:  0001356857 
Address:  6310 NANCY RIDGE DR SUITE 105 
City, State, Zip:  SAN DIEGO, California 92121 
Telephone:  858-452-0370 
Fiscal Year:  12/31 
Description of Business
We are a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections. We are developing tedizolid phosphate, a new, novel antibiotic, for the treatment of serious Gram-positive bacterial infections, including those caused by methicillin-resistant staphylococcus aureus, or MRSA. Tedizolid phosphate is being developed for acute bacterial skin and skin structure infections, or ABSSSI, and pneumonia, and potentially for other indications. ABSSSI is the current classification for complicated skin and skin structure infections. In addition, we are discovering antibiotics for infections caused by Gram-negative bacteria using our structure based discovery platform. In December 2011, we reported top line data from our first Phase 3 clinical trial, the ESTABLISH 1 (TR701-112) study, of the oral dosage form of tedizolid phosphate for the treatment of ABSSSI.
Register for EDGAR Pro and access this filing in:     
  FORM 8-K
    SECTION 5 CORPORATE GOVERNANCE
      Item 5.02 Departure of Directors or Certain Officers; ...
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01 Financial Statements and Exhibits.
    SIGNATURES
    INDEX TO EXHIBITS
  EXHIBIT 99.1
BROKERAGE PARTNERS